Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N02 ANALGESICS
N02A OPIOIDS
N02AX Other opioids
N02AX06 Tapentadol
D10199 Tapentadol hydrochloride (JAN) <JP/US>
USP drug classification [BR:br08302]
Analgesics
Opioid Analgesics, Long-acting
Tapentadol
D10199 Tapentadol hydrochloride (JAN)
Opioid Analgesics, Short-acting
Tapentadol
D10199 Tapentadol hydrochloride (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
8 Narcotics
82 Non-alkaloidal narcotics
821 Synthetic narcotics
8219 Others
D10199 Tapentadol hydrochloride (JAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01564 Opioid receptor agonist
DG01563 mu-Opioid receptor agonist
DG00826 Tapentadol
D10199 Tapentadol hydrochloride
Analgesic
DG01984 Opioid analgesics
DG00826 Tapentadol
D10199 Tapentadol hydrochloride
Metabolizing enzyme substrate
DG02924 UGT substrate
DG00826 Tapentadol
D10199 Tapentadol hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Opioid
OPRM1
D10199 Tapentadol hydrochloride (JAN) <JP/US>
Transporters
Solute carrier family
SLC6
SLC6A2 (NAT1)
D10199 Tapentadol hydrochloride (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10199
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10199
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10199
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10199
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01564 Opioid receptor agonist
DG01563 mu-Opioid receptor agonist
DG00826 Tapentadol
Analgesic
DG01984 Opioid analgesics
DG00826 Tapentadol
Metabolizing enzyme substrate
DG02924 UGT substrate
DG00826 Tapentadol